Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction

NCT: NCT02880618 · RECRUITING

NCT IDNCT02880618
StatusRECRUITING
Start Date2016-12-13
Completion2027-07
SponsorCVRx, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this registry (NCT02880618) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for heart failure with reduced ejection fraction (HFrEF).

Frequently Asked Questions

What is BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction?

BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction is a clinical trial registered under NCT02880618. Current status: RECRUITING.

What is the status of NCT02880618?

The current status of NCT02880618 (BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction) is: RECRUITING.

When did BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction start?

BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction started on 2016-12-13.

Related Devices

PMA P180050Stimulator, carotid sinus nerveCvrx, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑